Quantcast
Last updated on April 17, 2014 at 15:43 EDT

Latest Lorcaserin Stories

2012-10-31 15:25:38

SAN DIEGO, Oct. 31, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will provide a corporate update and report third quarter 2012 financial results after the NASDAQ Global Select Market closes on Tuesday, November 6, 2012. The company will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) that day to discuss the corporate update and financial results. The conference call may be accessed by dialing 877.643.7155 for...

2012-10-12 07:23:16

SAN DIEGO, Oct. 12, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in a Phase 1 multiple dose clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin (IP) receptor for the treatment of pulmonary arterial hypertension (PAH). This randomized, double-blind and placebo-controlled dose titration trial is planned to enroll up to 30 healthy adult volunteers, and will evaluate the...

2012-09-18 02:27:31

SAN DIEGO, Sept. 18, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the UBS Global Life Sciences Conference on Thursday, September 20, 2012, at 7:30 a.m. Eastern Time (4:30 a.m. Pacific Time) at the Grand Hyatt New York in New York City. A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the...

2012-08-09 10:25:51

SAN DIEGO, Aug. 9, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the second quarter ended June 30, 2012, and reviewed recent developments. At June 30, 2012, cash and cash equivalents totaled $143.8 million, which does not include (i) the $20.0 million milestone payment received from Eisai Inc. subsequent to June 30 for the inclusion of the efficacy and safety data from the Phase 3 BLOOM-DM (Behavioral modification and Lorcaserin for...

2012-07-29 22:20:41

WOODCLIFF LAKE, N.J., and SAN DIEGO, July 30, 2012 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Arena has transferred the BELVIQ(®) (lorcaserin hydrochloride) New Drug Application (NDA) to Eisai. The transfer establishes Eisai as the marketing authorization holder responsible for regulatory activities in the United States related to the commercialization of BELVIQ, including pharmacovigilance requirements. Arena will...

Qsymia: Third Weight-Loss Drug Approved BY FDA In Thirteen Years
2012-07-18 13:04:53

Lawrence LeBlond for redOrbit.com - Your Universe Online The second new weight-management drug in 13 years has been approved by US regulators for use in people who are obese or overweight and have certain medical conditions. The drug, Qsymia, developed by pharmaceutical company Vivus, received Food and Drug Administration (FDA) approval just a month after another anti-obesity drug, called Belviq, was given a thumbs up. Qsymia has been approved for use in obese adults with a body mass...

2012-07-17 18:20:20

WASHINGTON, July 17, 2012 /PRNewswire-USNewswire/ -- Today, members of the Obesity Care Continuum (OCC) commended the Food and Drug Administration (FDA) for their continued proactive approach to ensuring safe obesity treatment options for the more than 93 million Americans affected by the disease. (Logo: http://photos.prnewswire.com/prnh/20120531/DC16753LOGO ) "By approving another medication that will help healthcare professionals treat this disease more effectively, the FDA continues to...

2012-07-11 10:23:32

SAN DIEGO, July 11, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the filing with the Swiss health authority, Swissmedic, of a Marketing Authorization Application (MAA) for lorcaserin hydrochloride, an investigational drug candidate in Switzerland. The intended indication is as an adjunct to diet and exercise for weight control in patients with an initial body mass index (BMI) of 30 kg/m(2) or greater (obese), or 27 kg/m(2) or greater (overweight) in the...

2012-07-06 23:00:37

On June 27th, 2012, the US FDA approved the new diet pill Belviq. Belviq (lorcaserin), by Arena Pharmaceuticals, is the first weight-loss drug to be approved in 13 years, according to Reuters. In the briefing documents for the May 10th, 2012 FDA Endocrinologic and Metabolic Drugs Advisory Committee, reviewers expressed concerns on safety of Lorcaserin related mainly to heart problems. Another obesity drug, the popular Fen Phen, was withdrawn from the market in 1997; it was linked with heart...

2012-07-05 02:24:12

SAN DIEGO, July 5, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the promotion of Craig M. Audet to the position of Senior Vice President, Operations and Head of Global Regulatory Affairs. In his new role, Audet will serve as an executive officer of the company. Audet, 48, will oversee various operations at Arena, including investor relations and alliance management, and will continue to lead regulatory affairs. He joined the company in April 2011 as Vice...